Effective therapies have been developed to treat a subset of metastatic melanoma, including the use of kinase inhibitors (BRAF and MEK) and immune checkpoint blockade.1 Melanoma, however, has a high mutational burden,2 and a significant proportion of cases adapt to current therapies and progress. The gene discussed is MAP2K7; the disease is metastatic melanoma.